NeuroSense Therapeutics Announces Biomarker Data From ALS Phase 2b Clinical Trial; Met Its Safety And Efficacy Endpoints Including Reducing Functional And Respiratory Deterioration And Statistically Significant Changes In ALS-Related Biological...
NeuroSense Therapeutics Announces Biomarker Data From ALS Phase 2b Clinical Trial; Met Its Safety And Efficacy Endpoints Including Reducing Functional And Respiratory Deterioration And Statistically Significant Changes In ALS-Related Biological...
NeuroSense Therapeutics Announces Biomarker Data From ALS Phase 2b Clinical Trial; Met Its Safety And Efficacy Endpoints Including Reducing Functional And Respiratory Deterioration And Statistically Significant Changes In ALS-Related Biological Markers Indicating PrimeC's Biological Activity
NeuroSense Therapeutics宣布来自ALS第二期临床试验的生物标志物数据；满足其安全性和疗效终点，包括减少功能和呼吸恶化，并对与ALS相关的生物标志物产生显着统计的变化，表明PrimeC的生物活性。
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation
12个月的数据展示出铁含量的调节，与改善ALS生存率和疾病缓解相一致。
Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy
之前的结果显示，PrimeC将疾病进展放慢36％并改善了生存率，突显其作为一种具有转化性的ALS治疗方案可能性。
CAMBRIDGE, Mass., Aug. 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announces positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). This data provides additional insights that align with the Company's recent announcements of improved survival by 43% and slowed disease progression by 36%.
美国马萨诸塞州剑桥市，2024年8月1日 /美通社/-- 神经感知治疗有限公司（NASDAQ纳斯达克股票代码：NRSN）(“神经感知”)，一家开发用于治疗严重神经退行性疾病的新型治疗方案的生物技术公司，宣布来自于PARADIGM第二期研究的12个月的正面的铁生物标记物数据。该研究评估了PrimeC在患有肌萎缩侧索硬化症的人群中的安全性和疗效。该数据提供了额外的见解，与该公司最近宣布的改善生存率43％和减缓疾病进展36％相一致。